ClinicalTrials.gg
CompletedNCT01747044Updated Nov 9, 2026

Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy

A Phase 2 interventional study of Milnacipran and Placebo in Fibromylagia, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing milnacipran in Fibromyalgia — none open to participants now, none under way, none of them phase 3. Milnacipran · Fibromyalgia.

Enrollment
13th of 22
48 · median 54
Started
2013
the only one that year
Phase 2
4 of 22
none open now
Registered
20th of 22
by date
Lead sponsor
1 of 22
University Hospital, Clermont-Ferrand

Among the 22 studies testing milnacipran in Fibromyalgia, this one is the 13th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 2, and was the 20th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

None of the 22 studies testing milnacipran in Fibromyalgia is open now. The open studies under Fibromyalgia, anywhere →

About milnacipran

Milnacipran: first FDA approval 2009 (SAVELLA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing milnacipran in Fibromyalgia as a file.
02

Study summary

Fibromyalgia affects 0.7 to 3.3% of the adult population and 7-10 times more women than men. In France, the prevalence is 1.6% according to a French study conducted in 2009 and published in 2011 by Serge Perrot et al.

The definition of fibromyalgia was recently amended with particular consideration of cognitive and somatic symptoms, factors not involved in the initial criteria of the ACR classification. Several factors are in favor of a malfunction of the central modulation of pain and poorer performance noxious inhibitory controls descendants (DNIC: diffuse noxious inhibitory controls) have been demonstrated. In fibromyalgia patients, the DNIC (diffuse noxious inhibitory controls) are altered with less pain inhibition than controls. Dysfunction of the central pain modulation is widely described in the literature and contributes to pain complained of fibromyalgia.

According to the Recommendations of the European League Against Rheumatism (EULAR) 2006, antidepressants have a genuine analgesic efficacy in controlled studies. Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR. A review included five double-blind studies on 4,000 participants who took 100 mg or 200 mg milnacipran or placebo over a period of 8 weeks to 24 weeks. A moderate response was obtained for 40% of participants treated for each dose of milnacipran on the criteria of "at least 30% pain relief" Impression and global change. Substantial improvement with milnacipran compared to placebo has been shown.

To date, the link between the weakening of DNIC in fibromyalgia and effectiveness of drug treatment has not been shown.

This study aims to assess the degree of impairment of DNIC in fibromyalgia patients may be predictive of the efficacy of milnacipran.

Read the detailed description

Visit 1 Inclusion of the patient, Clinical examination, Evaluation of pain, basal Pain and cognitive tests

Visit 2 (can be coupled with Visit 1 if necessary) Randomisation of the patient and allocation of the treatment for 1 month.

Phone contact Visit 2 +7 days, + 15 days, +21 days Follow-up of the compliance of the treatment and collection of adverse events.

Visit 3 (follow up at 1 month) Evaluation of pain, Pain and cognitive tests End of study

03

Conditions studied

  • Fibromylagia

Browse trials for

Keywords

  • Fibromyalgia
  • Diffuse Noxious Inhibitory Controls
  • Milnacipran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient of more than 18 years old,
  • Patient with fibromyalgia

Exclusion criteria

Exclusion Criteria:

  • Patient with a to the administration of the milnacipran,
  • Patient with a concomitant spontaneous pain not attributable of fibromyalgia,
  • Patient with medical and/or surgical histories judged by the investigator not compatible with the trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Milnacipran

    Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR

    Drug: Milnacipran

  • Placebo comparator
    Capsules of lactose

    placebo over a period of 8 weeks to 24 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Pain scores on the verbal numeric scale

    Time frame: at T0 and T0+1 month

Secondary outcomes

  1. sensitivity and pain thresholds to a mechanical stimulus

    Time frame: at T0 and T0+1 month

  2. sensitivity and pain thresholds to a thermal stimulus

    Time frame: at T0 and T0+1 month

  3. scores on cognitive tests

    Time frame: at T0 and T0+1 month

  4. Adverse events record

    Time frame: at T0 and T0+1 month

07

Study locations

1 site
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Pickering G, Macian N, Delage N, Picard P, Cardot JM, Sickout-Arondo S, Giron F, Duale C, Pereira B, Marcaillou F. Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study. Drug Des Devel Ther. 2018 Aug 10;12:2485-2496. doi: 10.2147/DDDT.S162810. eCollection 2018. PubMed 30127596 ↗
  • Macian N, Pereira B, Shinjo C, Dubray C, Pickering G. Fibromyalgia, milnacipran and experimental pain modulation: study protocol for a double blind randomized controlled trial. Trials. 2015 Apr 3;16:134. doi: 10.1186/s13063-015-0659-4. PubMed 25873248 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Apr 2016, 35 months.

Of 24 phase 2 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 35 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Nov 2014 → Apr 2016 and completion Nov 2014 → Jun 2016.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2012
First posted
Dec 11, 2012
StartActual
Apr 29, 2013
Primary completionActual
Apr 9, 2016was Nov 2014
CompletionActual
Jun 9, 2016was Nov 2014
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 9, 2026
Primary completion
Nov 2014→Apr 9, 2016 (actual)
Nov 9, 2026
Study completion
Nov 2014→Jun 9, 2016 (actual)
Nov 9, 2026
Publications
Results publication added: Pickering G, Macian N, Delage N, Picard P, Cardot JM, Sickout-Arondo S, Giron F, Duale C, Pereira B, Marcaillou F. Milnacipran poorly modulates pain in patient… PubMed 30127596 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Status unknown→Completed
    Publications Results publication added: Pickering G, Macian N, Delage N, Picard P, Cardot JM, Sickout-Arondo S, Giron F, Duale C, Pereira B, Marcaillou F. Milnacipran poorly modulates pain in patient… PubMed 30127596 ↗
    Primary completion Nov 2014→Apr 9, 2016 (now actual)
    Study completion Nov 2014→Jun 9, 2016 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01747044
Collaborators
Dr. Gisèle PICKERING (MCU, PH) Center of clinical pharmacology/CIC Inserm-501 - Main investigator, Dr Pascale PICARD/ Dr Noémie Delage / Dr Fabienne RIAUX - Center of evaluation and treatment of the pain - Investigator, Dr Gilles DUCHEIX/ Center of clinical pharmacology/CIC Inserm-501 - Investigator, Dr Christian DUALE/ Center of clinical pharmacology/CIC Inserm-501 - Investigator
Responsible party
Sponsor
First posted
Dec 11, 2012
Start date
Apr 29, 2013
Primary completion
Apr 9, 2016
Completion
Jun 9, 2016
Last update
Nov 9, 2026

Study contacts

Gisèle PICKERING
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milnacipran

Start the discussion